Atossa Therapeutics, Inc.

NasdaqCM:ATOS Stock Report

Market Cap: US$153.5m

Atossa Therapeutics Valuation

Is ATOS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ATOS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ATOS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ATOS's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for ATOS?

Key metric: As ATOS is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ATOS. This is calculated by dividing ATOS's market cap by their current book value.
What is ATOS's PB Ratio?
PB Ratio2.1x
BookUS$73.68m
Market CapUS$153.48m

Price to Book Ratio vs Peers

How does ATOS's PB Ratio compare to its peers?

The above table shows the PB ratio for ATOS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average8.7x
ACHV Achieve Life Sciences
4.7x57.1%US$147.5m
GOSS Gossamer Bio
2.9x18.8%US$157.6m
SGMT Sagimet Biosciences
0.9x-33.5%US$153.2m
YMTX Yumanity Therapeutics
26.2xn/aUS$143.6m
ATOS Atossa Therapeutics
2.1x40.9%US$153.5m

Price-To-Book vs Peers: ATOS is good value based on its Price-To-Book Ratio (2.1x) compared to the peer average (2.8x).


Price to Book Ratio vs Industry

How does ATOS's PB Ratio compare vs other companies in the US Biotechs Industry?

61 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$554.58m
IMAB I-Mab
0.4x1.8%US$76.59m
ACET Adicet Bio
0.4x6.7%US$74.16m
MGX Metagenomi
0.3x-23.2%US$70.73m
ATOS 2.1xIndustry Avg. 1.9xNo. of Companies81PB01.63.24.86.48+
61 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ATOS is expensive based on its Price-To-Book Ratio (2.1x) compared to the US Biotechs industry average (1.9x).


Price to Book Ratio vs Fair Ratio

What is ATOS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ATOS PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ATOS's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ATOS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.22
US$5.83
+378.1%
22.5%US$7.00US$4.00n/a3
Nov ’25US$1.42
US$5.50
+287.3%
19.6%US$6.50US$4.00n/a3
Oct ’25US$1.46
US$5.50
+276.7%
19.6%US$6.50US$4.00n/a3
Sep ’25US$1.37
US$5.42
+295.4%
18.6%US$6.25US$4.00n/a3
Aug ’25US$1.29
US$5.42
+319.9%
18.6%US$6.25US$4.00n/a3
Jul ’25US$1.20
US$5.42
+351.4%
18.6%US$6.25US$4.00n/a3
Jun ’25US$1.30
US$5.33
+310.3%
17.7%US$6.00US$4.00n/a3
May ’25US$1.53
US$4.67
+205.0%
20.2%US$6.00US$4.00n/a3
Apr ’25US$2.00
US$4.58
+129.2%
18.0%US$5.75US$4.00n/a3
Mar ’25US$1.00
US$4.58
+358.3%
18.0%US$5.75US$4.00n/a3
Feb ’25US$0.84
US$4.88
+480.6%
17.9%US$5.75US$4.00n/a2
Jan ’25US$0.88
US$4.88
+454.0%
17.9%US$5.75US$4.00n/a2
Dec ’24US$0.76
US$4.75
+525.2%
15.8%US$5.50US$4.00n/a2
Nov ’24US$0.68
US$4.83
+615.9%
12.9%US$5.50US$4.00US$1.423
Oct ’24US$0.74
US$4.83
+556.3%
12.9%US$5.50US$4.00US$1.463
Sep ’24US$0.80
US$4.63
+476.7%
13.5%US$5.25US$4.00US$1.372
Aug ’24US$1.10
US$4.63
+320.5%
13.5%US$5.25US$4.00US$1.292
Jul ’24US$1.26
US$4.63
+267.1%
13.5%US$5.25US$4.00US$1.202
Jun ’24US$0.92
US$4.63
+401.4%
13.5%US$5.25US$4.00US$1.302
May ’24US$0.60
US$4.75
+691.7%
15.8%US$5.50US$4.00US$1.532
Apr ’24US$0.72
US$4.75
+555.3%
15.8%US$5.50US$4.00US$2.002
Mar ’24US$0.73
US$5.00
+582.8%
20.0%US$6.00US$4.00US$1.002
Feb ’24US$0.80
US$5.00
+525.0%
20.0%US$6.00US$4.00US$0.842
Jan ’24US$0.53
US$5.00
+846.1%
20.0%US$6.00US$4.00US$0.882
Dec ’23US$0.77
US$5.00
+552.7%
20.0%US$6.00US$4.00US$0.762
Nov ’23US$0.93
US$5.50
+494.2%
27.3%US$7.00US$4.00US$0.682

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies